Key statistics
On Monday, Innoviva Inc (INVA:NSQ) closed at 22.83, -9.21% below its 52-week high of 25.15, set on Feb 26, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 22.76 |
|---|---|
| High | 23.07 |
| Low | 22.69 |
| Bid | 17.00 |
| Offer | 26.86 |
| Previous close | 22.96 |
| Average volume | 856.31k |
|---|---|
| Shares outstanding | 74.07m |
| Free float | 73.33m |
| P/E (TTM) | 7.38 |
| Market cap | 1.69bn USD |
| EPS (TTM) | 3.10 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
- Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
- Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
